Evolus investors frown as FDA declines to approve Botox rival

Discussion in 'Market News' started by sniper-academy, May 16, 2018.


Draft saved Draft deleted
  1. sniper-academy

    sniper-academy Administrator Staff Member

    Joined:
    Sep 30, 2011
    Messages:
    262,638
    Likes Received:
    5
    U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.

    Continue reading...
     
Loading...

Share This Page